Earnings reports are critical events for investors as they provide insight into a company's financial health. UroGen Pharma's worse-than-expected Q4 EPS results likely led to decreased investor confidence and a subsequent drop in stock price. The direct correlation between earnings performance and stock price movement is well-documented, making this analysis highly relevant and important for investors in URGN.